Remove Anatomy Remove Innovation Remove Quality of Life
article thumbnail

New Treatment Options Available for Patients with Tricuspid Valve Disease

DAIC

Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention and the director of the Karsh Division of Interventional Cardiology in the Smidt Heart Institute at Cedars-Sinai, and his team of experts treat more than 10,000 patients every year. When might a minimally invasive procedure be the best approach?

article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies. This is reinforced by our continued innovation of the Evolut TAVR platform, which has delivered proven valve performance and durability to physicians and patients for years.

TAVR 111
article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

Deep venous anatomy and obstructions can present a multitude of complexities and mechanical challenges. Engineered for the unique demands of venous anatomy and obstructions, the Duo Venous Stent System is comprised of two stents – Duo Hybrid and Duo Extend – of various sizes. It is the third most common cardiovascular disease [2].

Stent 105
article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year. are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S

Tricuspid 105
article thumbnail

People With Tricuspid Valve Disease Have New Treatment Options

DAIC

Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention and the director of the Karsh Division of Interventional Cardiology in the Smidt Heart Institute at Cedars-Sinai, and his team of experts treat more than 10,000 patients every year. When might a minimally invasive procedure be the best approach?